Senolytics in 2026: Human Evidence, Failed Endpoints, and Clinic Safety Questions

No senolytic protocol has been shown to extend lifespan or healthspan in healthy humans.

Reviewed August 28, 2026: trial statuses, the current dasatinib label, human study sizes, endpoints, and safety claims were rechecked against ClinicalTrials.gov, DailyMed, and primary papers.

The field is scientifically credible but clinically early. Human studies are small, disease-specific, and mostly designed to test feasibility, biomarkers, or short-term safety. One phase 2 randomized trial of dasatinib plus quercetin missed its primary endpoint in the overall study population.¹

That distinction matters because some longevity clinics describe senolytics as if a plausible mechanism, a mouse study, and an intermittent drug schedule add up to proven preventive medicine. They do not.

This guide does not provide a dosing protocol. Dasatinib is an oncology drug with serious labeled risks, and a research regimen should not be copied into self-treatment or a generic anti-aging package.

What senolytics are supposed to do

Cellular senescence is a state in which a cell stops dividing and can release inflammatory or tissue-remodeling signals. Senescence can help with processes such as wound repair and cancer suppression, but persistent senescent cells may also contribute to age-related pathology.

Senolytics are intended to remove selected senescent cells. Senomorphics aim to modify their signaling without necessarily killing the cells.

The landmark 2011 mouse study used a genetic system to clear p16-positive cells and delayed several age-related disorders in a progeroid mouse model.² That was proof of biological principle in a model organism. It was not evidence that a pill clears every relevant senescent cell type or improves outcomes in healthy people.

Senescent cells are heterogeneous across tissues and diseases. A therapy that targets a retinal cell state may have little relevance to muscle, kidney, brain, or generalized aging. This is why the clinically serious programs are pursuing specific diseases and measurable endpoints rather than a universal rejuvenation claim.

What the human evidence actually shows

Study	Design and population	Main finding	What it does not prove
Diabetic kidney disease, 2019	Open-label pilot, 9 participants, dasatinib plus quercetin	Tissue and circulating senescence-associated markers decreased 11 days after a research course	No control group and no demonstration of better kidney outcomes, healthspan, or lifespan3
Mild Alzheimer’s disease, 2023	Open-label phase 1 pilot, 5 participants	Dasatinib reached cerebrospinal fluid in 4 participants; feasibility and tolerability were the main result	Cognitive and neuroimaging endpoints did not improve significantly; efficacy requires a powered randomized trial4
Bone metabolism, 2024	Phase 2 randomized controlled trial, 60 postmenopausal women	The primary endpoint, change in the bone-resorption marker CTx at 20 weeks, did not differ between groups	Exploratory subgroup signals do not establish a general treatment effect or a healthy-aging indication1
UBX1325 in diabetic macular edema, 2025	Sham-controlled trial, 65 participants	Safety was the primary objective; the visual-acuity estimate favored UBX1325 but its 95% confidence interval included no difference	The authors described possible efficacy signals and called for larger trials; it is not evidence for systemic anti-aging use5

The pattern is not “senolytics work” or “senolytics failed.” The defensible reading is narrower:

1. Some compounds can change senescence-associated biomarkers in small human studies.
2. Biomarker change is not the same as a patient-important outcome.
3. A randomized phase 2 study can miss its primary endpoint even when exploratory subgroups look interesting.
4. Disease, tissue, target, and patient selection may determine whether a signal exists.
5. Healthy-person prevention remains unproven.

Dasatinib plus quercetin is not a routine wellness stack

Dasatinib is FDA-labeled for specific forms of Philadelphia chromosome-positive leukemia. Its current label does not include senolysis, anti-aging, or healthy-person prevention.⁶

The same label warns that dasatinib can cause severe thrombocytopenia, neutropenia, and anemia; serious or fatal bleeding; fluid retention and pleural effusion; pulmonary arterial hypertension; and QT prolongation. It also has clinically important drug-interaction and pregnancy considerations.⁶

Quercetin being available as a supplement does not make the combination a supplement protocol. The risk profile is driven in part by a prescription oncology drug.

If a clinic offers dasatinib plus quercetin outside a registered trial, ask for all of the following in writing:

• the exact indication being treated;
• the prescriber’s identity and license;
• confirmation that the use is off-label;
• the primary human evidence for that indication;
• baseline screening and exclusion criteria;
• the laboratory and symptom monitoring plan;
• drug-interaction review;
• adverse-event and emergency procedures;
• the stopping rule;
• disclosure of any financial interest in the protocol.

“We use the same protocol as a study” is not enough. Study participants are selected, monitored, consented, and analyzed under a protocol that may not resemble a commercial package.

What about fisetin?

Fisetin has extensive preclinical interest and several human trials are registered. As of August 28, 2026, ClinicalTrials.gov listed disease- or function-specific studies in areas such as peripheral artery disease, vascular function, frailty, sepsis, and cancer survivorship.⁷

Registration does not mean success, approval, or proof of general anti-aging benefit. Some fisetin trials are recruiting or active, while others have been withdrawn, terminated, or completed without a published healthy-lifespan endpoint.

Do not infer that a commercially sold supplement is an established senolytic treatment in humans. Product purity, exposure, interactions, population, endpoints, and monitoring all matter. This guide deliberately does not reproduce study doses.

Can a clinic measure your senescent-cell burden?

There is no validated consumer test that can tell a healthy person they have a treatable whole-body burden of senescent cells.

Researchers are evaluating markers such as p16 transcripts and panels of senescence-associated secretory phenotype proteins. A 2025 paper characterized candidate assays for selecting participants in clinical trials, not for diagnosing a consumer condition or justifying a clinic package.⁸

CRP, IL-6, epigenetic clocks, and ordinary inflammatory panels are not senescence-specific. A clinic should not convert a nonspecific result into a diagnosis of “high senescent-cell burden.”

The active pipeline is disease-specific

ClinicalTrials.gov showed several active phase 1 or phase 2 programs on August 28, 2026. Examples included:

• dasatinib plus quercetin for Alzheimer’s disease, active but not recruiting;
• fisetin for peripheral artery disease and mobility impairment, recruiting;
• topical RLS-1496 for actinic keratosis, active but not recruiting.⁷

These trials test defined conditions, populations, routes, and endpoints. A topical actinic-keratosis program is not evidence that the same compound rejuvenates the whole body. An Alzheimer’s feasibility study is not a prevention protocol for healthy clients.

Trial statuses can change. Verify the registry record and posted results rather than relying on a clinic slide deck or a biotech press release.

A buyer gate for any senolytic offer

Question	Acceptable answer	Walk-away signal
What exact product is being used?	Generic and brand name, manufacturer, route, formulation, and written prescription	”Proprietary senolytic” without composition
What condition is being treated?	A defined diagnosis or a registered trial eligibility criterion	”Aging” or a vague high-burden score
What is its regulatory status?	Approved indication, clearly identified off-label use, or registered trial number	”FDA compliant” used to imply approval
What human endpoint supports it?	A primary paper in the same condition and population	Mouse lifespan, mechanism, testimonials, or biomarker change alone
Who monitors safety?	Named licensed clinician, baseline review, scheduled monitoring, and emergency pathway	Sales staff or a remote protocol with no escalation plan
What happens if you decline?	Evidence-based alternatives remain available	Pressure, scarcity, or bundling with an annual package

Do not buy when the clinic cannot identify the drug, indication, evidence, prescriber, or adverse-event pathway. Do not treat a biological-age score or an inflammatory panel as proof that senolysis is needed.

Questions patients commonly ask

Are senolytics FDA-approved?

There is no FDA-approved indication for anti-aging or senolysis in healthy people. Dasatinib is approved for specific leukemias, not as a longevity treatment.⁶

Is dasatinib plus quercetin safe?

There is no general safety answer for commercial anti-aging use. Small trials have reported feasibility or no serious adverse events in selected participants, but dasatinib’s label includes serious hematologic, bleeding, fluid-retention, pulmonary, and cardiac risks.⁴¹⁶

Can I take quercetin or fisetin on my own as a senolytic?

Human outcome evidence is insufficient to recommend either supplement as a proven senolytic strategy for healthy aging. A supplement label does not reproduce the product, exposure, screening, or monitoring used in a clinical trial.

When will next-generation senolytics be available?

There is no defensible approval date. Current programs are disease-specific and early phase. Availability depends on successful trials, regulatory review, manufacturing, and the indication tested.

Which longevity clinics offer senolytics?

Clinic menus change and an offer is not evidence of quality. Rather than ranking providers by availability, verify the exact product, regulatory status, evidence for your condition, prescriber, monitoring, and emergency pathway.

Bottom line

Senolytics remain an important research field. They are not established preventive medicine for healthy people.

The strongest human evidence shows early biomarker or feasibility signals in small disease-specific studies, alongside a randomized trial that missed its primary endpoint in the overall population. That is enough to justify research, not enough to justify routine anti-aging prescriptions.

If a clinic presents senolytics as proven rejuvenation, provides a copyable dosing schedule, diagnoses senescent-cell burden from nonspecific tests, or cannot explain dasatinib’s labeled risks, do not buy the protocol.

Footnotes

1. Farr JN, et al. “Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial.” Nature Medicine (2024). PMC ↩ ↩² ↩³

2. Baker DJ, et al. “Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders.” Nature (2011). PubMed ↩

3. Hickson LJ, et al. “Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.” eBioMedicine (2019). PMC ↩

4. Gonzales MM, et al. “Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial.” Nature Medicine (2023). PMC ↩ ↩²

5. Klier S, et al. “Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema.” NEJM Evidence (2025). PubMed ↩

6. DailyMed. SPRYCEL (dasatinib) prescribing information, updated August 21, 2026. ↩ ↩² ↩³ ↩⁴

7. U.S. National Library of Medicine. ClinicalTrials.gov search for senolytic studies, statuses reviewed August 28, 2026. RLS-1496 record: NCT07340697. ↩ ↩²

8. Farr JN, et al. “Characterization of Human Senescent Cell Biomarkers for Clinical Trials.” Aging Cell (2025). PMC ↩